- Conditions
- Thoracic Aorta, Thoracic Injuries, Blunt Injuries
- Interventions
- Zenith® TX2® Low Profile Endovascular Graft
- Device
- Lead sponsor
- Cook Research Incorporated
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 21
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Miami, Florida + 17 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 13,063
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Alzheimer's Disease
- Interventions
- MK-1942, Donepezil, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 4
- States / cities
- Rogers, Arkansas • Hallandale, Florida • Decatur, Georgia + 1 more
- Conditions
- High-Risk Non-Muscle-Invasive Bladder Cancer
- Interventions
- Cretostimogene Grenadenorepvec
- Drug
- Lead sponsor
- CG Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 79
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 70 more
- Conditions
- Alzheimer's Disease
- Interventions
- Dimebon, Placebo comparator
- Drug
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,003 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 52
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
- Conditions
- Myeloid Leukemia, Chronic, Chronic-Phase
- Interventions
- dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 724 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Alhambra, California • Anaheim, California + 33 more
- Conditions
- Primary Pulmonary Hypertension
- Interventions
- LIQ861 Inhaled Treprostinil
- Drug
- Lead sponsor
- Liquidia Technologies, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 30 more
- Conditions
- Ankle Equinus, Ankle Contracture, Diabetes Mellitus
- Interventions
- Standard of care, Dynasplint
- Other · Device
- Lead sponsor
- Dynasplint Systems, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Jonesboro, Georgia • Fort Worth, Texas
- Conditions
- Sickle Cell Disease
- Interventions
- Guided Relaxation, Acupuncture
- Behavioral · Other
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 379 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 2 more
- Conditions
- Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
- Interventions
- Soquelitinib, Belinostat, Pralatrexate
- Drug
- Lead sponsor
- Corvus Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 24
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 19 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Xaluritamig, Abiraterone acetate, Docetaxel, Cabazitaxel
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 46
- States / cities
- Goodyear, Arizona • Tucson, Arizona • Duarte, California + 37 more
- Conditions
- Growth Failure, Congenital Heart Disease
- Interventions
- New Infant Formula
- Other
- Lead sponsor
- Nutricia North America
- Industry
- Eligibility
- 1 Month to 8 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Jacksonville, Florida • Atlanta, Georgia • Greenville, North Carolina + 2 more
- Conditions
- Esophageal Fistula, Esophageal Neoplasms, Esophageal Perforation, Esophageal Stenosis, Stents
- Interventions
- Evolution® Esophageal Stent - Fully Covered
- Device
- Lead sponsor
- Cook Group Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Torrance, California • Atlanta, Georgia + 8 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Fasiglifam (TAK-875), Fasiglifam (TAK-875) Placebo, Sitagliptin, Sitagliptin Placebo, Metformin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 44
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Glendale, Arizona + 41 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Suptavumab 30 mg/kg, Placebo Matched to Suptavumab, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- Up to 6 Months
- Enrollment
- 1,177 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 107
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 104 more
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome
- Interventions
- ZX008 0.2 to 0.8 mg/kg/day, Cannabidiol
- Drug
- Lead sponsor
- Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Tacoma, Washington
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Exubera (inhaled insulin), 8-point glucose diary (to assess pre- and post prandial glucoses), Meal Tolerance Test, 24-hour continuous glucose monitoring (at select sites), Pulmonary Function Testing, Hypoglycemic Event Monitoring, Laboratory Assessments, Nutritional Counseling and Diabetes Education
- Drug · Procedure · Behavioral
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Britain, Connecticut + 13 more
- Conditions
- Glabellar Lines
- Interventions
- AGN-151586, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • Newport Beach, California • Redondo Beach, California + 9 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Mycophenolate Mofetil, Placebo for Mycophenolate Mofetil, Voclosporin, Placebo for Voclosporin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
- Interventions
- irinotecan hydrochloride, leucovorin calcium, fluorouracil, cetuximab, bevacizumab
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 382
- States / cities
- Fort Smith, Arkansas • Burbank, California • Castro Valley, California + 259 more
- Conditions
- Uterine Fibroids
- Interventions
- Telapristone Acetate, Placebo
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 47 Years · Female only
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 12 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Telaprevir, Peg-IFN-alfa-2a, Ribavirin, Placebo
- Drug
- Lead sponsor
- Tibotec BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Coronado, California • La Jolla, California + 28 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, Durvalumab, Erlotinib Hydrochloride, FGFR Inhibitor AZD4547, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Palbociclib, Pharmacological Study, Rilotumumab, Talazoparib, Taselisib, Tremelimumab
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 998
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more
- Conditions
- Perennial Allergic Rhinitis
- Interventions
- 0.15% azelastine hydrochloride, 0.1% azelastine hydrochloride, Placebo
- Drug
- Lead sponsor
- Meda Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 581 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 43
- States / cities
- Huntington Beach, California • Long Beach, California • Los Angeles, California + 35 more
- Conditions
- Acute Migraine
- Interventions
- Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo (matches lasmiditan doses)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Fountain Hills, Arizona + 67 more